Skip to main content
. 2020 Oct 26;35(11):6108–6116. doi: 10.1007/s00464-020-08105-2

Table 1.

Demographics characteristics

Variables All patients (n = 184, %) p-value LRLN lymph node dissection (n = 110, %) p-value
VAME (n = 75) RAME (n = 109) VAME (n = 40) Early RAME (n = 43) Last RAME (n = 27)
Age, years, mean ± SD 61.1 ± 6.6 60.0 ± 6.1 0.329 60 ± 6.1 59.6 ± 6.8 59.5 ± 5 0.845
Sex ratio (M:F) 65:10 90:19 0.453 35:5 36:7 23:4 0.941
Smoking (n, %) 48 (64.0) 72 (66.1) 0.774 27 (67.5) 28 (65.1) 20 (74.1) 0.758
Drinking (n, %) 46 (61.3) 77 (70.6) 0.187 22 (55.0) 29 (67.4) 21 (77.8) 0.148
Comorbidity
 Hypertension 18 (24.0) 42 (38.5) 0.039 9 (22.5) 15 (34.1) 11 (40.7) 0.259
 Diabetes 6 (8.0) 10 (9.2) 0.781 4 (10.0) 5 (11.6) 3 (10.9) 1.000
 Heart disease 5 (6.7) 13 (11.9) 0.238 1 (2.5) 5 (11.6) 3 (11.1) 0.266
Weight loss 0.958 0.290
 Yes 20 (23.5) 26 (23.9) 10 (25.0) 15 (34.9) 5 (18.5)
 No 65 (76.5) 83 (76.1) 30 (75.0) 28 (65.1) 22 (81.5)
Tumor location 0.481 0.817
 20–25 cm 7 (9.3) 8 (7.3) 3 (7.5) 2 (4.7) 2 (7.4)
 > 25 & ≤ 30 cm 29 (38.7) 35 (32.1) 12 (30.0) 14 (32.6) 10 (37.0)
 > 30 cm 36 (48.0) 64 (58.7) 23 (57.5) 27 (62.8) 14 (51.9)
 Mutitumor 3 (4.0) 2 (1.8) 2 (5.0) 0 (0) 1 (3.7)
Neoadjuvant chemoradiotherapy/chemotherapy 10/10 12/16 0.877 2/9 6/8 2/4 0.653
pCR 4 (20) 7 (25) 2 (18.2) 5 (35.7) 0 (0)
Pathological T stage 0.213 0.514
 0 4 (5.3) 8 (7.3) 2 (5.1) 5 (11.6) 1 (3.7)
 1 23 (30.7) 18 (16.5) 8 (20.5) 10 (23.3) 4 (14.8)
 2 14 (18.7) 26 (23.9) 11 (28.2) 9 (20.9) 4 (14.8)
 3 23 (30.7) 34 (31.2) 12 (30.8) 9 (20.9) 8 (29.6)
 4 11 (14.7) 23 (21.1) 6 (15.4) 10 (23.3) 10 (37.0)
Pathological N stage 0.327 0.113
 0 45 (60.0) 52 (47.7) 20 (50.0) 25 (58.1) 8 (29.6)
 1 15 (20.0) 29 (26.6) 10 (25.0) 12 (27.9) 8 (29.6)
 2 13 (17.3) 21 (19.3) 9 (22.5) 5 (11.6) 7 (25.9)
 3 2 (2.7) 7 (6.4) 1 (2.5) 1 (2.3) 4 (14.8)

LRLN left recurrent laryngeal nerve